More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials. (February 2017)

• Record Type: Journal Article
• Authors: Vasista, A.; Stockler, M.R.; West, T.; Wilcken, N.; Kiely, B.E.
• Is Part Of: Breast. Volume 31(2017)
• Page Start: 99
• Page End: 104
• Publication Date: 2017-02
• Subjects: Estimating survival times -- HER2-positive -- Metastatic breast cancer; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2016.10.007
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Objectives: To estimate worst-case, typical and best-case scenarios for survival as a communication aid for managing patients with HER2-positive metastatic breast cancer (MBC) starting HER2-targeted therapies. Methods: We sought randomised trials of HER2-targeted therapies and recorded the following percentiles (representative scenarios) from each OS curve: 90th (worst-case), 75th (lower-typical), 50th (median), 25th (upper-typical) and 10th (best-case). We then tested whether we could estimate these percentiles for each OS curve by multiplying its median by four simple multiples: 0.25 (to derive the 90th percentile), 0.5 (75th), 2 (25th) and 3 (10th). Estimates were deemed accurate if within 0.75–1.33 times the actual value. Results: We identified 15 trials with 4798 patients. For first-line, single-agent HER2-targeted therapy (15 treatment groups), the median (interquartile range [IQR]) for median OS was 33.3 months (29.1–38.4), and for each percentile was: 90th 9.5 months (7.7–11.0); 75th 19.2 months (16.4–20.8); and 25th 50.6 months (47.1–63.3). The 10th percentile was unavailable for all treatment groups. For first-line dual HER2-targeted therapy (1 treatment group), the median OS was 56.5 months. Simple multiples of the median OS accurately estimated the: 90th percentile in 79%; 75th percentile in 100%; and 25th percentile in 89% of OS curves. Conclusions: Surprisingly little is known of survival beyond the median for HER2-positive MBC. Longer trial follow-up is required to help clinicians estimate and explain the best-case scenario. Simple multiples of the median OS provide a reasonable framework for estimating then explaining survival times to patients.